Research programme: schizophrenia therapeutics - Myrobalan Therapeutics
Latest Information Update: 28 Apr 2024
At a glance
- Originator Myrobalan Therapeutics
- Class Antipsychotics; Small molecules
- Mechanism of Action Synaptic transmission modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 28 Apr 2024 Discontinued for Schizophrenia in USA (PO) (Myrobalan Therapeutics pipeline, April 2024)
- 04 Apr 2024 Early research in Schizophrenia in USA (PO) (Myrobalan Therapeutics pipeline, April 2024)